RxDoctor Payments Data

Lesa Klozenbucher

Nurse Practitioner · Hays, KSNPI 1417923327

Payments from drug & device makers

$764in general payments, 2019–2025

Across 39 payments — averaging $19.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$191
  • Sanofi$117
  • AstraZeneca$100
  • Boehringer Ingelheim$82
  • GSK$59
  • Regeneron Healthcare Solutions, Inc.$49
  • plus $164 from 9 others

What the payments were for

  • Food & beverage$74898%
  • Education$152%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$764 in reported general payments places this provider in the 70th percentile of 1,326 nurse practitioner providers in Kansas.

See all nurse practitioner providers in Kansas

Medicare billing

Part B allowed, 2024
$92,001
Medicare patients
546
Services billed
1,259

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter172$122,066
Spiriva RespimatTiotropium Bromide105$68,248
Dupixent SyringeDupilumab12$52,997
Breztri AerosphereBudesonide/Glycopyr/Formoterol56$37,356
Breo ElliptaFluticasone/Vilanterol82$37,207
Stiolto RespimatTiotropium Br/Olodaterol Hcl40$20,958
Incruse ElliptaUmeclidinium Bromide53$20,930
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr25$14,502
Spiriva HandihalerTiotropium Bromide26$13,300
Advair HfaFluticasone Propion/Salmeterol37$11,473
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate40$7,583
EliquisApixaban12$7,015
Zafirlukast75$6,792
SymbicortBudesonide/Formoterol Fumarate26$6,720
DuleraMometasone/Formoterol17$6,115

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta, Arnuity Ellipta$59$199,882353 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$82$89,206145 claims
AstraZenecaBreztri Aerosphere, Symbicort$100$44,07682 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,326 nurse practitioner providers in Kansas.

Other nurse practitioner in Hays

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →